Evive Biotech is a global biologics company focused on oncology and inflammatory disorders. Developing a portfolio of novel therapies to deliver life-saving treatments for patients worldwide, we are devoted to being the leading Asian biologics company in advancing truly novel biologic products from pre-clinical studies to U.S. BLA submission and commercial launch.
Revolutionary remedies for a healthy and happy world.
Enabling access to new treatment options for patients in need of effective medical solutions.
What’s Going On
Our innovative assets have recently achieved significant milestones, including the completion of F-627's global Phase III clinical trials, which met its primary and secondary endpoints, the BLA submission of F-627 to the US FDA, and the receipt of orphan drug designation from the US FDA for F-652. We are engaging with potential partners and the broader scientific community to share our successes and to ensure broad access to treatment options for patients.
Evive Biotech Announces the Appointment of Dr. Liping Sun as Senior VP, Global Head of R&D
U.S. FDA Accepts Biologics License Application for Ryzneuta™
Evive Biotech’s GMP Facility Receives Manufacture License of Pharmaceutical Products
Evive Biotech Submits Biologics License Application to US FDA for Ryzneuta™
Evive Biotech and Dr. Xiao Qiang Yan Form Joint Venture to Further Develop Bi-specific Antibody Platform ITab
Evive Biotech Announces First Patient Dosed in Phase 2 Study to Evaluate the Efficacy and Safety of F-652 in Patients with Moderate to Severe COVID-19